MXPA05014220A - Genes regulados en cancer ovarico como objetivos de pronostico y terapeuticos. - Google Patents

Genes regulados en cancer ovarico como objetivos de pronostico y terapeuticos.

Info

Publication number
MXPA05014220A
MXPA05014220A MXPA05014220A MXPA05014220A MXPA05014220A MX PA05014220 A MXPA05014220 A MX PA05014220A MX PA05014220 A MXPA05014220 A MX PA05014220A MX PA05014220 A MXPA05014220 A MX PA05014220A MX PA05014220 A MXPA05014220 A MX PA05014220A
Authority
MX
Mexico
Prior art keywords
ovarian cancer
prognostic
therapeutic targets
genes regulated
patient
Prior art date
Application number
MXPA05014220A
Other languages
English (en)
Inventor
Christian Nicolas Lavedan
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MXPA05014220A publication Critical patent/MXPA05014220A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invencion se refiere al uso de analisis genomicos para detectar la presencia de cancer ovarico en un paciente a partir de una muestra de tejido o sangre y a equipos para llevar a cabo esta determinacion. Ademas esta invencion se refiere a metodos para tratar un paciente con cancer ovarico.
MXPA05014220A 2003-07-02 2004-07-01 Genes regulados en cancer ovarico como objetivos de pronostico y terapeuticos. MXPA05014220A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48446503P 2003-07-02 2003-07-02
PCT/EP2004/007167 WO2005005661A2 (en) 2003-07-02 2004-07-01 Genes regulated in ovarian cancer as prognostic and therapeutic targets

Publications (1)

Publication Number Publication Date
MXPA05014220A true MXPA05014220A (es) 2006-03-09

Family

ID=34062046

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05014220A MXPA05014220A (es) 2003-07-02 2004-07-01 Genes regulados en cancer ovarico como objetivos de pronostico y terapeuticos.

Country Status (8)

Country Link
EP (1) EP1644522A2 (es)
JP (1) JP2007526749A (es)
CN (1) CN1845999A (es)
AU (1) AU2004256182A1 (es)
BR (1) BRPI0412110A (es)
CA (1) CA2531091A1 (es)
MX (1) MXPA05014220A (es)
WO (1) WO2005005661A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1899482A2 (en) * 2005-04-07 2008-03-19 Novartis Vaccines and Diagnostics, Inc. Ddr2 in cancer diagnosis, detection and treatment
EP1806413A1 (en) * 2006-01-06 2007-07-11 Oligene GmbH An in-vitro-method and means for determination of different tumor types and predicting success of surgical procedures in ovarian cancer
AU2007321070B2 (en) * 2006-11-13 2013-11-21 Valipharma Methods and uses involving genetic abnormalities at chromosome 12
GB0815846D0 (en) * 2008-09-01 2008-10-08 Immunovia Ab diagnosis, prognosis and imaging of disease
WO2011085263A2 (en) 2010-01-11 2011-07-14 Genomic Health, Inc. Method to use gene expression to determine likelihood of clinical outcome of renal cancer
CA2809342A1 (en) * 2010-08-27 2012-03-01 Universitaetsklinikum Muenster Means and methods for the detection of a predisposition of a female subject to recurrent pregnancy loss (rpl), preeclampsia (pe) and/or fetal growth restriction (fgr)
ES2829415T3 (es) 2013-05-30 2021-05-31 Genomic Health Inc Algoritmo de perfil de expresión génica para calcular una puntuación de recurrencia para un paciente con cáncer de riñón
CN103920150B (zh) * 2014-04-17 2016-02-03 北京大学第一医院 Satb1在治疗皮肤t细胞淋巴瘤中的应用
JP6436477B2 (ja) * 2014-05-13 2018-12-12 国立大学法人大阪大学 癌治療用医薬組成物
JP6168625B2 (ja) * 2016-01-12 2017-07-26 国立研究開発法人産業技術総合研究所 上皮性卵巣癌鑑別マーカー
CN106841622B (zh) * 2017-04-07 2019-01-18 南通大学附属医院 Scml2在诊断胃肠胰神经内分泌肿瘤中的应用
CN108085392A (zh) * 2018-01-09 2018-05-29 山大生殖研发中心有限公司 上皮性卵巢癌的生物标志物及其用途
CN110241198A (zh) * 2019-05-30 2019-09-17 成都吉诺迈尔生物科技有限公司 一种表征hHRD同源重组缺陷的基因组重组指纹及其鉴定方法
CN112229999B (zh) * 2020-09-01 2022-04-22 浙江省肿瘤医院 一种卵巢癌的预后诊断标志物Claudin21及其应用
CN113684277B (zh) * 2021-09-06 2022-05-17 南方医科大学南方医院 一种基于基因组拷贝数变异的生物标志物预测卵巢癌同源重组缺陷的方法及应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001018542A2 (en) * 1999-09-03 2001-03-15 Millennium Pharmaceuticals, Inc. Identification, assessment, prevention, and therapy of ovarian cancer
AU4592601A (en) * 2000-03-21 2001-10-03 Millennium Predictive Medicine Novel genes, compositions, kits, and method for identification, assessment, prevention, and therapy of ovarian cancer
US20030003479A1 (en) * 2001-04-19 2003-01-02 Millennium Pharmaceutical, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
AU2002324881A1 (en) * 2001-09-05 2003-03-18 Wesleyan University Diagnostic and prognostic tests

Also Published As

Publication number Publication date
EP1644522A2 (en) 2006-04-12
WO2005005661A2 (en) 2005-01-20
BRPI0412110A (pt) 2006-11-21
WO2005005661A3 (en) 2005-07-14
CN1845999A (zh) 2006-10-11
AU2004256182A1 (en) 2005-01-20
JP2007526749A (ja) 2007-09-20
CA2531091A1 (en) 2005-01-20

Similar Documents

Publication Publication Date Title
MXPA05014220A (es) Genes regulados en cancer ovarico como objetivos de pronostico y terapeuticos.
WO2005084109A3 (en) Cancer specific gene mh15
AU2003253986A1 (en) Gene expression profiling in biopsied tumor tissues
WO2005100998A3 (en) Membrane markers for use in cancer diagnosis and therapy
GB2467467C (en) TAZ/WWTR1 for diagnosis and treatment of cancer
WO2007015947A3 (en) Methods and kits for the prediction of therapeutic success, recurrence free and overall survival in cancer therapies
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
TW200626900A (en) Wnt proteins and detection and treatment of cancer
HK1108284A1 (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for cdk2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
MX2007006529A (es) Seleccionar pacientes para terapia con un inhibidor her.
TW200626899A (en) Frizzled proteins and detection and treatment of cancer
WO2006133325A3 (en) Analysis of tissue samples surrounding malignancies
AU2002303444A1 (en) Detection of microsatellite instability and its use in diagnosis of tumors
WO2005040421A3 (en) Prognostic and diagnostic markers for cell proliferative disorders of the breast tissues
WO2004106495A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
AU2003293141A1 (en) Methods for identifying risk of breast cancer and treatments thereof
MX2009005941A (es) Ensayos de diagnostico complementario para terapia de cancer.
WO2009019370A3 (fr) Procede de dosage de l'apolipoproteine aii pour le diagnostic in vitro du cancer colorectal
ATE426162T1 (de) Verfahren zum untersuchen von kírperflussikeiten auf krebszellen sowie entsprechende analysekits
WO2005014846A3 (en) Methods for identifying risk of breast cancer and treatments thereof
WO2007020522A3 (en) Protein markers for diagnosing of colorectal cancer and use of said markers as drug targets for the treatment of said cancer type
WO2009019369A3 (fr) Procede de dosage de la plastine-i pour le diagnostic in vitro du cancer colorectal
WO2007071829A3 (en) Methods and means related to diseases
WO2002059611A3 (en) Diagnosis and treatment of cancer using mammalian pellino polypeptides and polynucleotides
MY147511A (en) Method for the detection and diagnosis of cancer involving primers and probes for the specific detection of the mage-a3-marker

Legal Events

Date Code Title Description
FA Abandonment or withdrawal